Drug
MK0633
MK0633 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 66.7%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_1
1
33%
Ph phase_2
2
67%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
terminated133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)
NCT00421278
terminatedphase_2
The Effect of MK0633 in Patients With Chronic Asthma (0633-007)
NCT00404313
completedphase_1
MK0633 Single Dose Study in Japanese Asthmatic Children Aged 12 to Less Than 16 Years (0633-028)
NCT00768170
Clinical Trials (3)
Showing 3 of 3 trials
NCT00421278Phase 2
The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)
NCT00404313Phase 2
The Effect of MK0633 in Patients With Chronic Asthma (0633-007)
NCT00768170Phase 1
MK0633 Single Dose Study in Japanese Asthmatic Children Aged 12 to Less Than 16 Years (0633-028)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3